文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-EB-PSMA放射性配体治疗转移性去势抵抗性前列腺癌患者的单臂低剂量前瞻性研究

A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2022-11-03

该单臂前瞻性研究纳入30例经紫杉烷类化疗及二代雄激素剥夺治疗失败的转移性去势抵抗性前列腺癌患者,每8周接受约2.0 GBq(55 mCi)177Lu-EB-PSMA、最多3周期。33.3%患者出现3级血液学不良事件,56.7%患者PSA下降≥50%,中位PSA无进展生存期4.6个月(95%CI 2.7-6.5),中位总生存期12.6个月(95%CI 8.1-17.1);作者认为其PSA应答与血液学毒性可能与7.4 GBq 177Lu-PSMA-617、4-6周期方案相当,需更多周期研究评估PFS和OS获益。

要点

  • 30例经紫杉烷化疗和二代雄激素剥夺治疗失败的mCRPC患者接受约2.0 GBq 177Lu-EB-PSMA、最多3周期。
  • 33.3%患者发生3级血液学不良事件,17例(56.7%)PSA下降≥50%。
  • 中位PSA无进展生存期4.6个月(95%CI 2.7-6.5),中位总生存期12.6个月(95%CI 8.1-17.1)。

核心结论

  • 基于约2.0 GBq 177Lu-EB-PSMA、最多3周期的放射性配体治疗可能获得与7.4 GBq 177Lu-PSMA-617、最多4-6周期方案相当的PSA应答和血液学毒性。
  • 作者认为需要更多周期的177Lu-EB-PSMA放射性配体治疗研究来评估PFS和OS方面的潜在获益。

研究设计与样本

  • 单臂、低剂量、前瞻性研究,纳入30例经紫杉烷类化疗和二代雄激素剥夺治疗后进展的转移性去势抵抗性前列腺癌男性患者。
  • 所有患者每8周接受约2.0 GBq(55 mCi)177Lu-EB-PSMA、最多3周期。
  • 主要终点为治疗安全性(血液学状态、肝功能、肾功能变化)及治疗疗效(PSA应答和分子影像应答);次要终点为PSA无进展生存期和总生存期;另一终点为患者报告的健康相关生活质量。
  • 2019年1月至2021年12月期间,分别有30例、22例、11例患者接受1、2、3周期177Lu-EB-PSMA放射性配体治疗。

主要发现

  • 整个随访期间,33.3%患者发生3级血液学不良事件。
  • 17例(56.7%)患者达到PSA下降至少50%。
  • 中位PSA无进展生存期为4.6个月(95%CI 2.7-6.5个月),中位总生存期为12.6个月(95%CI 8.1-17.1个月)。
  • 较高的全身PSMA SUVmean与更好的PSA应答相关,较高的基线碱性磷酸酶和较大的总PSMA阳性肿瘤体积与更差的PSA无进展生存期相关,存在内脏转移和较高的基线PSA值是总生存期更差的显著预后因素。
  • 177Lu-EB-PSMA放射性配体治疗后健康相关生活质量结局显著改善。

关键数值与推荐

  • 每周期约2.0 GBq(55 mCi)177Lu-EB-PSMA,8周间隔,最多3周期。
  • PSA应答定义为PSA下降至少50%,17例(56.7%)达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需要更多周期的177Lu-EB-PSMA放射性配体治疗研究来评估PFS和OS方面的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to investigate the safety and therapeutic efficacy of radioligand therapy (RLT) of 177Lu-EB-prostate-specific membrane antigen (PSMA) in patients with metastatic castration-resistant prostate cancer. Methods: Thirty men with progressive metastatic castration-resistant prostate cancer previously treated with taxane-based chemotherapy and second-generation androgen deprivation therapy were enrolled. All patients received up to 3 cycles of approximately 2.0 GBq (55 mCi) of 177Lu-EB-PSMA per cycle at 8-wk intervals. The primary endpoint was therapeutic safety, including changes in hematologic status, liver function, and renal function. An additional primary endpoint was therapeutic efficacy, including prostate-specific antigen (PSA) response and molecular imaging response. The secondary endpoints were PSA progression-free survival (PFS) and overall survival (OS). Another endpoint was patient-reported health-related quality of life. Results: From January 2019 to December 2021, 30, 22, and 11 patients received 1, 2, or 3 cycles of 177Lu-EB-PSMA RLT, respectively. During the entire follow-up period, 33.3% of patients experienced grade 3 hematologic adverse events. Seventeen (56.7%) patients achieved a PSA reduction of at least 50%. The median PSA PFS was 4.6 mo (95% CI, 2.7-6.5 mo), and the median OS was 12.6 mo (95% CI, 8.1-17.1 mo). A higher whole-body PSMA SUVmean correlated with a better PSA response, higher baseline alkaline phosphatase and larger total PSMA-positive tumor volume were associated with worse PSA PFS, and the existence of visceral metastases and higher PSA value at baseline were significant prognosticators of worse OS. Health-related quality-of-life outcomes improved significantly after 177Lu-EB-PSMA RLT. Conclusion: RLT based on approximately 2.0 GBq of 177Lu-EB-PSMA for up to 3 cycles may achieve a PSA response and hematologic toxicity comparable to those from 7.4-GBq doses of 177Lu-PSMA-617 for up to 4-6 cycles. Further studies with more cycles of 177Lu-EB-PSMA RLT are needed to evaluate the potential benefits in terms of PFS and OS.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang G, Zang J, Jiang Y, et al. A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2022. PMID: 36328486. doi:10.2967/jnumed.122.264857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。